Business
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
CBP-201 global AD data accepted as an e-Poster with an Oral Presentation CBP-201 China AD trial data accepted as a late-breaking Oral Presentation SAN DIEGO
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"\nCBP-201 global AD data accepted as an e-Poster with an Oral Presentation\nCBP-201 China AD trial data accepted as a late-breaking Oral Presentation\n\n SAN DIEGO & TAICANG & SUZHOU, China--(BUSINESS WIRE)--\nConnect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD), March 17-21, 2023, in New Orleans, LA. Specifically, data from the Phase 2b CBP-201 global trial in moderate-to-severe AD will be presented as an online e-poster with an oral presentation. Data from stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe AD has been accepted as a late-breaking abstract for oral presentation.\n\nOnline e-Poster with Oral Presentation\n\n“Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001)”\n\nOnline Oral Presentation and e-Poster: March 17, 2:30-2:35 PM Central Time\n\nAbstract: #4448\n\nLate-Breaker Oral Presentation\n\n“CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002)”\n\nMarch 18, 2023, 1:40 PM – 1:50 PM Central Time, New Orleans Ernest N. Morial Convention Center Theater B\n\n“We are delighted that abstracts from our global and China-only CBP-201 trials in atopic dermatitis have been accepted by the AAD for oral presentation, and in particular that our China trial data was granted the late-breaking abstract distinction,” said Zheng Wei, Ph.D., Co-founder and CEO of Connect Biopharma. “We look forward to sharing our AD data, which we believe will continue to demonstrate CBP-201 differentiation, at this prestigious conference.”\n\nAbout Connect Biopharma Holdings Limited\n\nConnect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to tr...